Skip to main navigation Skip to search Skip to main content

Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I)

  • Zhenghong Peng
  • , David S. Maxwell
  • , Duoli Sun
  • , Basvoju A. Bhanu Prasad
  • , Paul T. Schuber
  • , Ashutosh Pal
  • , Yunming Ying
  • , Dongmei Han
  • , Liwei Gao
  • , Shimei Wang
  • , Alexander Levitzki
  • , Vaibhav Kapuria
  • , Moshe Talpaz
  • , Matthew Young
  • , Hollis D. Showalter
  • , Nicholas J. Donato
  • , William G. Bornmann*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

A series of degrasyn-like symmetrical compounds have been designed, synthesized, and screened against B cell malignancy (multiple myeloma, mantle cell lymphoma) cell lines. The lead compounds T5165804 and CP2005 showed higher nanomolar potency against these tumor cells in comparison to degrasyn and inhibited Usp9x activity in vitro and in intact cells. These observations suggest that this new class of compounds holds promise as cancer therapeutic agents.

Original languageEnglish
Pages (from-to)1450-1458
Number of pages9
JournalBioorganic and Medicinal Chemistry
Volume22
Issue number4
DOIs
StatePublished - 15 Feb 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Degrasyn
  • Inhibitors
  • Jak2/Stat3
  • Multiple myeloma
  • Small molecules
  • Synthesis

Fingerprint

Dive into the research topics of 'Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I)'. Together they form a unique fingerprint.

Cite this